The Cochlear (ASX:COH) share price has surged nearly 30% in 2021

This comes after the medical recently hit a 52-week high.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Limited (ASX: COH) share price has surged more than 29% since the start of the year. Following a tough 2020, Cochlear has been one of the standout performers in the S&P/ASX 50 Index (ASX: XFL) for 2021.

A strong half year report and pipeline of demand have seen investors clamour for shares in the company. Read on to find out more on the Cochlear share price.

What's been driving the Cochlear share price?

After a tumultuous 2020, shares in Cochlear have burst out the blocks in 2021 having recently hit a new 52-week high.

Despite the company not releasing any price-sensitive news, a promising half year report and a strong recovery potential could be what's driving investors to the company.

For the 6 months to December 31, Cochlear recorded a 2% fall in total revenue to $743.2 million, while underlying net profit climbed 4% to $125.3 million.

Although Cochlear reported an 8% slide in sales revenue in the first quarter of FY21 2021, sales rebounded strongly in the second quarter, up 7% on a constant currency basis.

Cochlear attributed the performance to varying degrees of growth across established and emerging markets. The better than expected result saw Cochlear return the government funding it had received as part of JobKeeper. In addition, Cochlear resumed paying dividends, declaring a $1.15 dividend, representing 60% of underlying profits.

What is the outlook for Cochlear?

Cochlear and the hearing implant sector were hit hard during the COVID-19 pandemic as elective surgeries ceased globally. Despite a sudden decline, implant surgery rates began to recover late last year.

As a result, Cochlear forecasts that it will achieve an underlying net profit for FY21 between $225 million and $245 million. This forecast reflects a 46% to 59% increase on last year's FY20 result.

Cochlear noted that a successful rollout of COVID-19 vaccines will see elective surgeries return to their pre-pandemic levels. The company noted that implant surgery rates have bounced back strongly in developed markets.

The recovery in emerging markets such as India and Brazil is expected to be more protracted. Emerging markets account for 20% of Cochlear's sales revenue. However, multiple strains and rising COVID cases are expected to subdue the recovery.

Cochlear hopes to return to its historical 70% dividend ratio in the near future and expects that the implant market will return to normal growth in financial year 2022-23.  

Should you invest $1,000 in Kogan.com Limited right now?

Before you buy Kogan.com Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Kogan.com Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Blue Chip Shares

Beautiful holiday photo showing two deck chairs close-up with people sitting in them enjoying the bright blue ocean and island view while sipping champagne and enjoying the good life thanks to Pilbara Minerals share price gains in recent times
Blue Chip Shares

3 ASX 200 blue chips to compound your way to riches

Analysts think these blue chips would be top picks for buy and hold investors.

Read more »

A businessman hugs his computer and smiles.
Blue Chip Shares

3 excellent ASX shares I would buy and hold for the next 10 years

Analysts think these quality companies could be in the buy zone right now.

Read more »

A group of people in suits watch as a man puts his hand up to take the opportunity.
Blue Chip Shares

The ultimate blue chip portfolio: 3 ASX 200 stocks to anchor your investments

Starting your investment journey? Here are three stocks that Goldman Sachs rates very highly.

Read more »

Happy shareholders clap and smile as they listen to a company earnings report.
Blue Chip Shares

3 quality ASX stocks that could lead the next market rebound

These stocks are highly rated by analysts for a reason. Here's what you need to know.

Read more »

Happy woman in front of padlocks
Blue Chip Shares

3 of the best ASX 200 blue chip shares to buy now

Analysts think these quality stocks would be top picks right now.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Blue Chip Shares

3 quality ASX shares to buy before the market rebounds

These shares are highly rated by analysts. Let's see why they are bullish.

Read more »

Male building supervisor stands and smiles with his arms crossed at a building site with workers behind him.
Blue Chip Shares

3 reasons to buy this 'high-quality' $14 billion ASX 200 stock today

A leading expert forecasts a big potential turnaround for this beaten down ASX 200 stock.

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Blue Chip Shares

3 leading ASX 200 blue chip shares to buy after the market selloff

Let's see which shares analysts are recommending to clients.

Read more »